NITROUS OXIDE, USP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NITROUS OXIDE, USP (NITROUS OXIDE, USP).
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
| Metabolism | Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination. |
| Excretion | Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination. |
| Protein binding | <0.5% (minimally bound; essentially unbound in plasma). |
| Volume of Distribution | 0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset). |
| Bioavailability | Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane). |
| Onset of Action | Inhalation: 30–60 seconds (analgesia at 20–50% concentration; anesthesia at 50–70%). |
| Duration of Action | 2–5 minutes after discontinuation; clinical effects dissipate rapidly due to fast pulmonary elimination; full recovery usually within 5–10 minutes. |
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
| Dosage form | GAS |
| Renal impairment | No dose adjustment required; nitrous oxide is minimally excreted renally. |
| Liver impairment | No dose adjustment required; metabolism is minimal. |
| Pediatric use | Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%. |
| Geriatric use | Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NITROUS OXIDE, USP (NITROUS OXIDE, USP).
| Breastfeeding | Nitrous oxide is rapidly eliminated from plasma; low levels may pass into breast milk. No published M/P ratio. After a single dose, breastfeeding can be resumed once the mother is alert and has recovered from anesthesia. Limited data suggest no adverse effects on nursing infants. Caution with repeated or high doses. |
| Teratogenic Risk | Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery. |
■ FDA Black Box Warning
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
| Serious Effects |
Absolute: Known hypersensitivity, severe hematologic abnormalities (e.g., megaloblastic anemia), active vitamin B12 deficiency, need for prolonged oxygen therapy (e.g., pneumothorax, bowel obstruction), air trapping conditions (e.g., middle ear surgery, sinus infection). Relative: Pregnancy (first trimester), neurological disease, folate deficiency.
| Precautions | Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard. |
Loading safety data…
| Fetal Monitoring | For pregnant patients, continuous pulse oximetry and capnography are recommended during administration. Monitor fetal heart rate if prolonged exposure (>30 minutes) or if maternal hypoxia is suspected. Assess maternal oxygen saturation and end-tidal nitrous oxide concentrations to minimize risk of hypoxia. |
| Fertility Effects | Occupational exposure to subanesthetic concentrations has been associated with reduced fertility and increased risk of spontaneous abortion in female healthcare workers. However, with proper scavenging systems, no adverse effects on fertility are observed. Single, brief anesthetic exposures do not appear to impair fertility. |